Development and Phase I Clinical Testing of an Intranasal Formulation of Interferon-beta-1a
May 19, 2004
Source: Nastech Pharmaceutical Company Inc.
Henry R. Costantino and Gordon Brandt
Nastech has developed and tested an intranasal formulation of interferon-beta-1a suitable for initial human clinical testing for the treatment of multiple sclerosis. An in vitro screening method was successfully employed to identity a candidate intranasal formulation of interferon-beta-1a. An early human clinical study suggested that there was about 20-25 percent bioavailability for this formulation. Ongoing work has identified an improved formulation.
Copyright © 2004, PRNewswire